C5b-9 Antibody (2A1)

• Reactivity: Rt
• Applications: WB, ELISA, Flow, ICC/IF, IHC
• Clone: 2A1
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

C5b-9 Antibody (2A1) Summary

• Immunogen: Rat C5b-9
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
  • Immunoassay
  • Immunocytochemistry/ Immunofluorescence
  • Immunohistochemistry
  • Immunohistochemistry-Frozen
  • Immunohistochemistry-Paraffin
  • Western Blot
• Application Notes: Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. IA: plates were coated with 30 ug/ml in 50 mM carbonatebuffer, pH 10.6 for 16 h at 4 degrees C. WB: A non-reduced sample treatment and SDS-Page was used. The band size is >200 kDa. IHC-P: Tissue sections fixed in formalin were pretreated with protease type XXIV for 10 minutes at 37 degrees C before incubation. IHC-F: Tissue sections were fixed in acetone for 10 minutes at room temperature before incubation.

Packaging, Storage & Formulations

• Storage: Store at 4°C.
• Buffer: PBS
• Preservative: No Preservative
• Purity: Protein G purified

Alternate Names for C5b-9 Antibody (2A1)

• MAC
• Membrane attack complex
• sC5-b9
• sC5b-9
• TCC
• Terminal complement complex

Background

The monoclonal antibody 2A1 recognizes rat C5b-9. The antibody was shown to compete with antibodies to human C9 for its binding site on the C5b-9 complex, indicating that the reactive epitope is located on the C9 molecule. C5b-9 membrane attack complexes are assembled from five precursor molecules in the serum. Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 complex. The last step of C5b-9 complex formation involves polymerization of C9 which accompanies insertion of the complex into the cell membrane. During formation of C5b-8 and C9 polymerization, neoantigens are generated which are unique to the C5b-9 complex and are not present on any of the individual native complex components. The complement regulatory proteins CD59 and complement S-protein can both prevent C5b-9 insertion into the cell membrane. The formed SC5b-9 complex is unable to attach to cells and is cytolytically inactive.C5b-9 is involved in the progression of chronic proteinuric renal disease by mediating continuous tubulointerstitial damage. Early tubulointerstitial injury in the remnant kidney can be improved when C5b-9 complex forming is abrogated. The monoclonal antibody 2A1 was raised against a rat C5b-9 neoantigen. Monoclonal antibody 2A1 can be used as a coating antibody to detect C5b-9 in plasma and urine samples.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for C5b-9 Antibody (NBP2-77377)(1)

Publication using NBP2-77377

• Holste KG, Ye F, Koduri S et al. Attenuation of ventriculomegaly and iron overload after intraventricular hemorrhage by membrane attack complex inhibition Journal of neurosurgery 2023-11-10 [PMID: 37948699]